Ginkgo Bioworks Holdings, Inc.DNANYSE
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
29.95%
↓ 58% below average
Average (22q)
71.56%
Historical baseline
Range
High:1757.80%
Low:-67.15%
Volatility
2550.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 29.95% |
| Q2 2025 | -24.75% |
| Q1 2025 | -7.14% |
| Q4 2024 | -0.82% |
| Q3 2024 | -42.63% |
| Q2 2024 | -1.64% |
| Q1 2024 | 16.59% |
| Q4 2023 | -25.29% |
| Q3 2023 | 8.58% |
| Q2 2023 | -11.29% |
| Q1 2023 | -10.22% |
| Q4 2022 | -30.71% |
| Q3 2022 | -9.86% |
| Q2 2022 | -10.36% |
| Q1 2022 | -67.15% |
| Q4 2021 | 1757.80% |
| Q3 2021 | 1.90% |
| Q2 2021 | -12.68% |
| Q1 2021 | -2.62% |
| Q4 2020 | 69.65% |
| Q3 2020 | 11.78% |
| Q2 2020 | 6.73% |
| Q1 2020 | 0.00% |